SXTC
China SXT Pharmaceuticals, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$671K
5Y Perf.-100.0%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
SXTC vs CODA vs MNDO vs SBFM
Revenue, margins, valuation, and 5-year total return — side by side.
CODA
Coda Octopus Group, Inc.
Aerospace & Defense
Market Cap$136M
5Y Perf.+116.3%
MNDO
MIND C.T.I. Ltd
Software - Application
Market Cap$20M
5Y Perf.-47.3%
SBFM
Sunshine Biopharma, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$737K
5Y Perf.-99.4%
SXTC vs CODA vs MNDO vs SBFM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | SXTC | CODA | MNDO | SBFM |
|---|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Aerospace & Defense | Software - Application | Drug Manufacturers - Specialty & Generic |
| Market Cap | $671K | $136M | $20M | $737K |
| Revenue (TTM) | $2M | $28M | $19M | $36M |
| Net Income (TTM) | $-3M | $4M | $3M | $-6M |
| Gross Margin | 21.1% | 66.3% | 51.0% | 33.3% |
| Operating Margin | -154.0% | 17.4% | 10.7% | -17.9% |
| Forward P/E | — | 22.8x | 7.6x | — |
| Total Debt | $984K | $395K | $929K | $952K |
| Cash & Equiv. | $18M | $29M | $8M | $10M |
SXTC vs CODA vs MNDO vs SBFM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
SXTC
CODA
MNDO
SBFM
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| China SXT Pharmaceu… (SXTC) | 100 | 0.0 | -100.0% |
| Coda Octopus Group,… (CODA) | 100 | 216.3 | +116.3% |
| MIND C.T.I. Ltd (MNDO) | 100 | 52.7 | -47.3% |
| Sunshine Biopharma,… (SBFM) | 100 | 0.6 | -99.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SXTC vs CODA vs MNDO vs SBFM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MNDO leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and capital preservation and lower volatility. Coda Octopus Group, Inc. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. SBFM also leads in specific categories worth noting. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
SXTC
China SXT Pharmaceuticals, Inc.
The Secondary Option
SXTC lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
CODA
Coda Octopus Group, Inc.
The Income Pick
CODA is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.
- Dividend streak 0 yrs, beta 0.99
- 8.6% 10Y total return vs MNDO's 65.7%
- Lower volatility, beta 0.99, Low D/E 0.7%, current ratio 8.86x
- Beta 0.99, current ratio 8.86x
Best for: income & stability and long-term compounding
MNDO
MIND C.T.I. Ltd
The Value Play
MNDO carries the broadest edge in this set and is the clearest fit for value and stability.
- Better valuation composite
- Beta 0.05 vs SBFM's 1.33, lower leverage
- 22.0% yield; the other 3 pay no meaningful dividend
- 8.6% ROA vs SBFM's -19.7%, ROIC 8.6% vs -42.9%
Best for: value and stability
SBFM
Sunshine Biopharma, Inc.
The Growth Play
SBFM is the clearest fit if your priority is growth exposure.
- Rev growth 44.7%, EPS growth 97.9%, 3Y rev CAGR 434.5%
- 44.7% revenue growth vs SXTC's -9.7%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | SBFM | 44.7% revenue growth vs SXTC's -9.7% |
| Value | MNDO | Better valuation composite |
| Quality / Margins | CODA | 14.8% margin vs SXTC's -189.8% |
| Stability / Safety | MNDO | Beta 0.05 vs SBFM's 1.33, lower leverage |
| Dividends | MNDO | 22.0% yield; the other 3 pay no meaningful dividend |
| Momentum (1Y) | CODA | +78.9% vs SXTC's -99.4% |
| Efficiency (ROA) | MNDO | 8.6% ROA vs SBFM's -19.7%, ROIC 8.6% vs -42.9% |
SXTC vs CODA vs MNDO vs SBFM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
FY 2025
Segment breakdown not available.
SXTC vs CODA vs MNDO vs SBFM — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCODALAGGINGSBFM
Who Leads Where
CODA leads in 3 of 6 categories
SXTC leads 0 • MNDO leads 0 • SBFM leads 0 • 2 tied
Explore the data ↓SBFMSunshine Biopharma, I…
0leads
MNDOMIND C.T.I. Ltd
0leads
SXTCChina SXT Pharmaceuti…
0leads
CODACoda Octopus Group, I…
3leads
6 Total Categories
CATEGORYLEADERvs SXTCvs MNDOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CODA5/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CODA6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
CODA6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CODA leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SBFM is the larger business by revenue, generating $36M annually — 20.9x SXTC's $2M. CODA is the more profitable business, keeping 14.8% of every revenue dollar as net income compared to SXTC's -189.8%. On growth, CODA holds the edge at +28.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | SXTCChina SXT Pharmac… | CODACoda Octopus Grou… | MNDOMIND C.T.I. Ltd | SBFMSunshine Biopharm… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $2M | $28M | $19M | $36M |
| EBITDAEarnings before interest/tax | -$3M | $6M | $2M | -$6M |
| Net IncomeAfter-tax profit | -$3M | $4M | $3M | -$6M |
| Free Cash FlowCash after capex | -$2M | $7M | $4M | -$9M |
| Gross MarginGross profit ÷ Revenue | +21.1% | +66.3% | +51.0% | +33.3% |
| Operating MarginEBIT ÷ Revenue | -154.0% | +17.4% | +10.7% | -17.9% |
| Net MarginNet income ÷ Revenue | -189.8% | +14.8% | +13.4% | -17.4% |
| FCF MarginFCF ÷ Revenue | -134.8% | +24.6% | +20.9% | -26.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -7.8% | +28.8% | -6.0% | +1.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -119.1% | +3.0% | -23.4% | +21.5% |
CODA leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
Evenly matched — MNDO and SBFM each lead in 2 of 5 comparable metrics.
Valuation Metrics
At 7.6x trailing earnings, MNDO trades at a 77% valuation discount to CODA's 32.7x P/E. On an enterprise value basis, MNDO's 5.5x EV/EBITDA is more attractive than CODA's 18.3x.
| Metric | SXTCChina SXT Pharmac… | CODACoda Octopus Grou… | MNDOMIND C.T.I. Ltd | SBFMSunshine Biopharm… |
|---|---|---|---|---|
| Market CapShares × price | $670,507 | $136M | $20M | $736,836 |
| Enterprise ValueMkt cap + debt − cash | -$16M | $108M | $13M | -$8M |
| Trailing P/EPrice ÷ TTM EPS | -0.20x | 32.73x | 7.62x | -0.14x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 22.85x | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | 7.64x | — | — |
| EV / EBITDAEnterprise value multiple | — | 18.25x | 5.51x | — |
| Price / SalesMarket cap ÷ Revenue | 0.39x | 5.14x | 1.04x | 0.02x |
| Price / BookPrice ÷ Book value/share | 0.04x | 2.34x | 0.89x | 0.03x |
| Price / FCFMarket cap ÷ FCF | — | 22.60x | 5.09x | — |
Evenly matched — MNDO and SBFM each lead in 2 of 5 comparable metrics.
Profitability & Efficiency
CODA leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
MNDO delivers a 11.9% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $-25 for SBFM. CODA carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to SXTC's 0.06x. On the Piotroski fundamental quality scale (0–9), CODA scores 7/9 vs SBFM's 1/9, reflecting strong financial health.
| Metric | SXTCChina SXT Pharmac… | CODACoda Octopus Grou… | MNDOMIND C.T.I. Ltd | SBFMSunshine Biopharm… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -21.4% | +7.2% | +11.9% | -24.6% |
| ROA (TTM)Return on assets | -15.2% | +6.6% | +8.6% | -19.7% |
| ROICReturn on invested capital | -142.0% | +11.2% | +8.6% | -42.9% |
| ROCEReturn on capital employed | -17.9% | +8.1% | +7.8% | -25.2% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 | 4 | 1 |
| Debt / EquityFinancial leverage | 0.06x | 0.01x | 0.04x | 0.04x |
| Net DebtTotal debt minus cash | -$17M | -$28M | -$7M | -$9M |
| Cash & Equiv.Liquid assets | $18M | $29M | $8M | $10M |
| Total DebtShort + long-term debt | $983,877 | $394,932 | $929,000 | $952,480 |
| Interest CoverageEBIT ÷ Interest expense | -4.14x | — | — | -757.53x |
CODA leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
CODA leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CODA five years ago would be worth $15,586 today (with dividends reinvested), compared to $1 for SBFM. Over the past 12 months, CODA leads with a +78.9% total return vs SXTC's -99.4%. The 3-year compound annual growth rate (CAGR) favors CODA at 11.0% vs SBFM's -89.9% — a key indicator of consistent wealth creation.
| Metric | SXTCChina SXT Pharmac… | CODACoda Octopus Grou… | MNDOMIND C.T.I. Ltd | SBFMSunshine Biopharm… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -99.4% | +27.3% | -15.4% | -18.0% |
| 1-Year ReturnPast 12 months | -99.4% | +78.9% | -31.7% | -14.6% |
| 3-Year ReturnCumulative with dividends | -99.8% | +36.8% | -25.3% | -99.9% |
| 5-Year ReturnCumulative with dividends | -100.0% | +55.9% | -35.4% | -100.0% |
| 10-Year ReturnCumulative with dividends | -100.0% | +861.1% | +65.7% | -100.0% |
| CAGR (3Y)Annualised 3-year return | -87.6% | +11.0% | -9.2% | -89.9% |
CODA leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — CODA and MNDO each lead in 1 of 2 comparable metrics.
Risk & Volatility
MNDO is the less volatile stock with a 0.05 beta — it tends to amplify market swings less than SBFM's 1.33 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CODA currently trades 70.1% from its 52-week high vs SXTC's 0.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | SXTCChina SXT Pharmac… | CODACoda Octopus Grou… | MNDOMIND C.T.I. Ltd | SBFMSunshine Biopharm… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.19x | 0.99x | 0.05x | 1.33x |
| 52-Week HighHighest price in past year | $1046.98 | $17.28 | $1.54 | $2.43 |
| 52-Week LowLowest price in past year | $0.08 | $5.98 | $0.98 | $0.95 |
| % of 52W HighCurrent price vs 52-week peak | +0.2% | +70.1% | +64.3% | +43.2% |
| RSI (14)Momentum oscillator 0–100 | 29.3 | 48.3 | 27.4 | 56.2 |
| Avg Volume (50D)Average daily shares traded | 53K | 255K | 38K | 37K |
Evenly matched — CODA and MNDO each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
MNDO is the only dividend payer here at 22.05% yield — a key consideration for income-focused portfolios.
| Metric | SXTCChina SXT Pharmac… | CODACoda Octopus Grou… | MNDOMIND C.T.I. Ltd | SBFMSunshine Biopharm… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | — | — |
| Price TargetConsensus 12-month target | — | $14.00 | — | — |
| # AnalystsCovering analysts | — | 1 | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — | +22.0% | — |
| Dividend StreakConsecutive years of raises | — | 0 | 0 | — |
| Dividend / ShareAnnual DPS | — | — | $0.22 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.6% | +100.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CODA leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
Best OverallCoda Octopus Group, Inc. (CODA)Leads 3 of 6 categories
Loading custom metrics...
SXTC vs CODA vs MNDO vs SBFM: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is SXTC or CODA or MNDO or SBFM a better buy right now?
For growth investors, Sunshine Biopharma, Inc.
(SBFM) is the stronger pick with 44. 7% revenue growth year-over-year, versus -9. 7% for China SXT Pharmaceuticals, Inc. (SXTC). MIND C. T. I. Ltd (MNDO) offers the better valuation at 7. 6x trailing P/E, making it the more compelling value choice. Analysts rate Coda Octopus Group, Inc. (CODA) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SXTC or CODA or MNDO or SBFM?
On trailing P/E, MIND C.
T. I. Ltd (MNDO) is the cheapest at 7. 6x versus Coda Octopus Group, Inc. at 32. 7x.
03Which is the better long-term investment — SXTC or CODA or MNDO or SBFM?
Over the past 5 years, Coda Octopus Group, Inc.
(CODA) delivered a total return of +55. 9%, compared to -100. 0% for Sunshine Biopharma, Inc. (SBFM). Over 10 years, the gap is even starker: CODA returned +861. 1% versus SBFM's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SXTC or CODA or MNDO or SBFM?
By beta (market sensitivity over 5 years), MIND C.
T. I. Ltd (MNDO) is the lower-risk stock at 0. 05β versus Sunshine Biopharma, Inc. 's 1. 33β — meaning SBFM is approximately 2476% more volatile than MNDO relative to the S&P 500. On balance sheet safety, Coda Octopus Group, Inc. (CODA) carries a lower debt/equity ratio of 1% versus 6% for China SXT Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — SXTC or CODA or MNDO or SBFM?
By revenue growth (latest reported year), Sunshine Biopharma, Inc.
(SBFM) is pulling ahead at 44. 7% versus -9. 7% for China SXT Pharmaceuticals, Inc. (SXTC). On earnings-per-share growth, the picture is similar: Sunshine Biopharma, Inc. grew EPS 97. 9% year-over-year, compared to -129. 1% for China SXT Pharmaceuticals, Inc.. Over a 3-year CAGR, SBFM leads at 434. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SXTC or CODA or MNDO or SBFM?
Coda Octopus Group, Inc.
(CODA) is the more profitable company, earning 15. 5% net margin versus -189. 8% for China SXT Pharmaceuticals, Inc. — meaning it keeps 15. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CODA leads at 17. 1% versus -154. 0% for SXTC. At the gross margin level — before operating expenses — CODA leads at 66. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Which pays a better dividend — SXTC or CODA or MNDO or SBFM?
In this comparison, MNDO (22.
0% yield) pays a dividend. SXTC, CODA, SBFM do not pay a meaningful dividend and should not be held primarily for income.
08Is SXTC or CODA or MNDO or SBFM better for a retirement portfolio?
For long-horizon retirement investors, MIND C.
T. I. Ltd (MNDO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 05), 22. 0% yield). Both have compounded well over 10 years (MNDO: +65. 7%, SBFM: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between SXTC and CODA and MNDO and SBFM?
These companies operate in different sectors (SXTC (Healthcare) and CODA (Industrials) and MNDO (Technology) and SBFM (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: SXTC is a small-cap quality compounder stock; CODA is a small-cap high-growth stock; MNDO is a small-cap deep-value stock; SBFM is a small-cap high-growth stock. MNDO pays a dividend while SXTC, CODA, SBFM do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(SXTC: -7.8% · CODA: 28.8%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.